Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Plasma cell 1Myeloid 1Gynecologic 1Gastrointestinal 1Breast 1

Conditions

Carcinoma, Non-Small-Cell Lung 302Parkinson Disease 4, Autosomal Dominant Lewy Body 180Melanoma 166Neoplasms 133Squamous Cell Carcinoma of Head and Neck 126Neoplasm Metastasis 98Colorectal Neoplasms 96Carcinoma, Renal Cell 80Triple Negative Breast Neoplasms 75Head and Neck Neoplasms 72Stomach Neoplasms 70Lung Neoplasms 68Breast Neoplasms 60Ovarian Neoplasms 56Carcinoma, Transitional Cell 51Uterine Cervical Neoplasms 44Endometrial Neoplasms 44Pancreatic Neoplasms 43Urinary Bladder Neoplasms 40Esophageal Neoplasms 40Carcinoma, Hepatocellular 37Small Cell Lung Carcinoma 30Cholangiocarcinoma 24Prostatic Neoplasms 22Carcinoma 22Lymphoma 20Carcinoma, Squamous Cell 20Recurrence 17Sarcoma 16Esophageal Squamous Cell Carcinoma 16

Interventions

ruxolitinib 21Azacitidine 5ponatinib 4parsaclisib 4nilotinib 4itacitinib 4anagrelide 3Phlebotomy 3Imatinib Mesylate 3INCB039110 3Aspirin 311-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene 3venetoclax 2pemigatinib 2luspatercept 2imetelstat 2givinostat hydrochloride 2givinostat 2fedratinib 2asciminib 2INCB057643 2Gemcitabine 2GRN163L peptide 2spartalizumab 1sonidegib 1selinexor 1sabatolimab 1rucaparib 1pembrolizumab 1navitoclax 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Myeloproliferative Disorders × pembrolizumab × Clear all
NCT02393248 2023-01-06

Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101)

Incyte Corporation

Phase 1/2 Terminated
201 enrolled 71 charts
BreastGastrointestinalGynecologicMyeloidPlasma cellThoracic

Breast Neoplasms, Lung Neoplasms, Multiple Myeloma, Myeloproliferative Disorders, Stomach Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡